BioCryst Pharmaceuticals, Inc.

Symbol: BCRX

NASDAQ

5.34

USD

Market price today

  • -5.2755

    P/E Ratio

  • 0.2057

    PEG Ratio

  • 1.10B

    MRK Cap

  • 0.00%

    DIV Yield

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.98%

Operating Profit Margin

-0.25%

Net Profit Margin

-0.59%

Return on Assets

-0.45%

Return on Equity

0.25%

Return on Capital Employed

-0.26%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Jon P. Stonehouse
Full-time employees:536
City:Durham
Address:4505 Emperor Boulevard
IPO:1994-03-04
CIK:0000882796

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

General Outlook

When we look at how much money they make before expenses, they keep 0.985% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.252%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.587%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.446% return, is a testament to BioCryst Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. BioCryst Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.251%. Furthermore, the proficiency of BioCryst Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.258% return on capital employed.

Stock Prices

BioCryst Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $4.77, while its low point bottomed out at $4.15. This variance in figures offers investors a lucid insight into the roller-coaster ride that is BioCryst Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing BCRX liquidity ratios reveals its financial health of the firm. The current ratio of 372.83% gauges short-term asset coverage for liabilities. The quick ratio (70.32%) assesses immediate liquidity, while the cash ratio (70.32%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio372.83%
Quick Ratio70.32%
Cash Ratio70.32%

Profitability Ratios

BCRX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -58.69% underscores its earnings before tax deductions. The net income per EBT, 100.00%, and the EBT per EBIT, 232.65%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -25.23%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-58.69%
Net Income per EBT100.00%
EBT per EBIT232.65%
EBIT per Revenue-25.23%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.73, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding70
Days of Inventory Outstanding2009
Operating Cycle2008.88
Days of Payables Outstanding803
Cash Conversion Cycle1205
Payables Turnover0.45
Inventory Turnover0.18
Fixed Asset Turnover39.80
Asset Turnover0.76

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.49, and free cash flow per share, -0.50, depict cash generation on a per-share basis. The cash per share value, 0.41, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.29, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.49
Free Cash Flow per Share-0.50
Cash per Share0.41
Operating Cash Flow Sales Ratio-0.29
Free Cash Flow to Operating Cash Flow Ratio1.02
Cash Flow Coverage Ratio-9.13
Capital Expenditure Coverage Ratio-50.45
Dividend Paid and Capex Coverage Ratio-50.45

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.37%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.03, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.19%, and total debt to capitalization, 3.19%, ratios shed light on its capital structure. An interest coverage of -1.59 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.37%
Debt Equity Ratio0.03
Long Term Debt to Capitalization3.19%
Total Debt to Capitalization3.19%
Interest Coverage-1.59
Cash Flow to Debt Ratio-9.13
Company Equity Multiplier1.39

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.72, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.18, reflects the portion of profit attributed to each share. The book value per share, -2.37, represents the net asset value distributed per share, while the tangible book value per share, -2.37, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.72
Net Income Per Share-1.18
Book Value Per Share-2.37
Tangible Book Value Per Share-2.37
Shareholders Equity Per Share-2.37
Interest Debt Per Share4.92
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 22.37%, indicates top-line expansion, while the gross profit growth, 23.03%, reveals profitability trends. EBIT growth, 30.13%, and operating income growth, 30.13%, offer insights into operational profitability progression. The net income growth, 8.33%, showcases bottom-line expansion, and the EPS growth, 11.28%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth22.37%
Gross Profit Growth23.03%
EBIT Growth30.13%
Operating Income Growth30.13%
Net Income Growth8.33%
EPS Growth11.28%
EPS Diluted Growth11.28%
Weighted Average Shares Growth3.38%
Weighted Average Shares Diluted Growth3.38%
Operating Cash Flow Growth41.22%
Free Cash Flow Growth40.37%
10-Year Revenue Growth per Share449.36%
5-Year Revenue Growth per Share761.50%
3-Year Revenue Growth per Share1519.26%
10-Year Operating CF Growth per Share-3.03%
5-Year Operating CF Growth per Share44.82%
3-Year Operating CF Growth per Share39.66%
10-Year Net Income Growth per Share-116.16%
5-Year Net Income Growth per Share-20.12%
3-Year Net Income Growth per Share-0.30%
10-Year Shareholders Equity Growth per Share69.04%
5-Year Shareholders Equity Growth per Share66.59%
3-Year Shareholders Equity Growth per Share61.26%
Receivables Growth12.55%
Inventory Growth4.18%
Asset Growth-6.01%
Book Value per Share Growth69.71%
Debt Growth14.47%
R&D Expense Growth-15.15%
SGA Expenses Growth34.21%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,887,532,020, captures the company's total value, considering both debt and equity. Income quality, 0.42, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.60, gauges operational efficiency, while the research and development to revenue, 64.85%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value1,887,532,020
Income Quality0.42
Sales General and Administrative to Revenue0.60
Research and Development to Revenue64.85%
Capex to Operating Cash Flow2.28%
Capex to Revenue-0.65%
Capex to Depreciation-131.00%
Stock-Based Compensation to Revenue16.78%
Graham Number7.93
Return on Tangible Assets-43.82%
Graham Net Net-2.73
Working Capital345,978,000
Tangible Asset Value-455,528,000
Net Current Asset Value-476,522,000
Invested Capital-2
Average Receivables53,774,500
Average Payables17,624,500
Average Inventory28,108,000
Days Sales Outstanding63
Days Payables Outstanding1207
Days of Inventory On Hand1658
ROIC-27.19%
ROE0.50%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.27, and the price to book ratio, 3.27, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.10, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -10.66, and price to operating cash flows, -10.86, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.27
Price to Book Ratio3.27
Price to Sales Ratio3.10
Price Cash Flow Ratio-10.86
Price Earnings to Growth Ratio0.21
Enterprise Value Multiple-14.43
Price Fair Value3.27
Price to Operating Cash Flow Ratio-10.86
Price to Free Cash Flows Ratio-10.66
Price to Tangible Book Ratio-2.53
Enterprise Value to Sales5.70
Enterprise Value Over EBITDA-18.50
EV to Operating Cash Flow-19.84
Earnings Yield-19.68%
Free Cash Flow Yield-8.45%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of BioCryst Pharmaceuticals, Inc. (BCRX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -5.275 in 2024.

What is the ticker symbol of BioCryst Pharmaceuticals, Inc. stock?

The ticker symbol of BioCryst Pharmaceuticals, Inc. stock is BCRX.

What is company IPO date?

IPO date of BioCryst Pharmaceuticals, Inc. is 1994-03-04.

What is company current share price?

Current share price is 5.340 USD.

What is stock market cap today?

The market cap of stock today is 1101807540.000.

What is PEG ratio in 2024?

The current 0.206 is 0.206 in 2024.

What is the number of employees in 2024?

In 2024 the company has 536.